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Schistosomiasis remains a major cause of morbidity in the world. The challenge 
today is not so much in the clinical management of individual patients, but rather 
in population-based control of transmission in endemic areas. Despite recent large-
scale efforts, such as integrated control programs aimed at limiting schistosomiasis by 
improving education and sanitation, molluscicide treatment programs and chemotherapy 
with praziquantel, there has only been limited success. There is an urgent need for 
complementary approaches, such as vaccines. We demonstrated previously that 
anti-oxidant enzymes, such as Cu–Zn superoxide dismutase (SOD) and glutathione S 
peroxidase (GPX), when administered as DNA-based vaccines induced significant levels 
of protection in inbred mice, greater than the target 40% reduction in worm burden 
compared to controls set as a minimum by the WHO. These results led us to investigate 
if immunization of non-human primates with antioxidants would stimulate an immune 
response that could confer protection as a prelude study for human trials. Issues of 
vaccine toxicity and safety that were difficult to address in mice were also investigated. 
All baboons in the study were examined clinically throughout the study and no adverse 
reactions occurred to the immunization. When our outbred baboons were vaccinated 
with two different formulations of SOD (SmCT-SOD and SmEC-SOD) or one of GPX 
(SmGPX), they showed a reduction in worm number to varying degrees, when compared 
with the control group. More pronounced, vaccinated animals showed decreased bloody 
diarrhea, days of diarrhea, and egg excretion (transmission), as well as reduction of eggs 
in the liver tissue and in the large intestine (pathology) compared to controls. Specific 
IgG antibodies were present in sera after immunizations and 10 weeks after challenge 
infection compared to controls. Peripheral blood mononuclear cells, mesenteric, and 
inguinal node cells from vaccinated animals proliferated and produced high levels of 
cytokines and chemokines in response to crude and recombinant antigens compared 
with controls. All together, these data demonstrate the potential of antioxidants as a 
vaccine in a non-human primate model.
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introduction
Schistosomiasis remains a major cause of morbidity in the world. 
The disease is endemic in 76 countries of the world where it affects 
some 200 million people (1). Substantial research has established 
that school-aged children in endemic areas are at significant risk 
of serious disease resulting from infection with schistosomes (2, 
3). Lack of access to clean water and sanitation and inadequate 
personal hygiene are important shared risk factors for these infec-
tions (4).
Currently, chemotherapy with praziquantel (PZQ) is the 
preferred treatment for schistosomiasis (5–8). Control pro-
grams based on mass chemotherapy are complicated by rapid 
and frequent re-infection and the difficulties and expense of 
maintaining these programs over a long term (9–12). There is 
evidence that schistosomes develop drug resistance against PZQ 
in some regions (13, 14), and there is additional evidence for 
serious rebound morbidity if regular and periodic treatments are 
interrupted (15–17). Despite recent large-scale efforts, integrated 
control programs aimed at limiting schistosomiasis by improv-
ing education and sanitation, molluscicide treatment programs 
to reduce the population of the intermediate snail host, and 
chemotherapy have had limited success (18). Effective control 
of schistosomiasis could prevent up to 130,000 deaths and avert 
up to 25 million disability adjusted life years lost annually (19). 
The challenge today is not so much in the clinical management 
of individual patients, but rather in population-based control of 
transmission (and consequently, of morbidity) in endemic areas. 
Because current control strategies employing chemotherapy with 
PZQ have not reduced transmission and morbidity to acceptable 
levels, there is an urgent need for complementary approaches, 
such as vaccines for schistosomiasis (20, 21).
Our own studies have focused on antioxidant enzymes as 
vaccine candidates [recently reviewed by Huang et al. (22)]. We 
hypothesized that antioxidants play a role in protecting the adult 
worms from damage derived from reactive oxygen species (23–26). 
To begin to test this hypothesis, we demonstrated that expres-
sion of the schistosome antioxidant enzymes [Cu-Zn superoxide 
dismutase (SOD); glutathione S peroxidase (GPX)] is developmen-
tally regulated such that the lowest levels of gene expression (as 
measured by transcription) and enzyme specific activity were in the 
larval stages, the most susceptible to immune killing, and highest in 
adult worms, the least susceptible to immune elimination (23, 25, 
27–29). To provide direct evidence that antioxidant enzymes were 
important in immune evasion (25) and thus were viable candidate 
vaccines, we used DNA vaccination strategies to demonstrate 
the efficacy of DNA constructs encoding either Cu/Zn cytosolic 
superoxide dismutase (SmCT-SOD), signal peptide-containing 
SOD (SmSP-SOD, also known as SmEC-SOD), or glutathione 
peroxidase (SmGPX) to be protective against Schistosoma mansoni 
infection in a murine challenge model. Employing different doses 
of plasmid cDNA constructs, mice exhibited a significant level 
of worm burden reduction when challenged with S. mansoni 
cercariae after immunization with SmCT-SOD (54%) and SmGPX 
(43.4%) from six independent experiments (29).
The WHO has identified several candidate vaccine antigens 
for independent evaluation, but none fulfilled the required 
standards in trials with mice. One of the criteria was a worm 
burden reduction of >40% in a murine challenge model (30). 
We have demonstrated that both SmCT-SOD and SmGPX were 
each capable as DNA-based (plasmid or vaccinia virus vehicles) 
vaccines to consistently induce significant levels of protection in an 
S. mansoni murine-challenge model, greater than the target 40% 
reduction in worm burden compared to control set as a minimum 
by the WHO. We also demonstrated in a mouse model that DNA 
encoding SmCT-SOD as a vaccine is able to significantly reduce 
worm burden by targeting adult S. mansoni worms 21 days and 
older (31).
The above results with the antioxidant enzymes in a murine 
model of S. mansoni encouraged us to investigate if immuniza-
tion of non-human primates with antioxidants would stimulate 
an immune response that would be safe and that could confer 
protection.
Materials and Methods
animals and screening
Young wild caught Olive Baboons (Papio cynocephalus anubis), 
both males and females aged 4–5 years, were from schistoso-
miasis non-endemic areas and habituated and quarantined for 
90 days in accordance with good animal welfare standards. The 
baboons were screened for the presence of several infections 
and parasites (such as malaria, tuberculosis, leishmaniasis, 
nematodes, etc.) before they were assigned to the study. For 
assessing the presence of current Schistosoma infections, the 
fecal material was examined for the presence of eggs and 
the serum from each animal was checked for the presence of 
antibodies against soluble egg antigens (SEA). Positive animals 
were excluded from our study or when necessary successfully 
treated using ivermectin and/or metro-nidazole as appropriate, 
months before the start of immunization. Detailed hematologi-
cal tests certified all animals were in excellent health during 
their quarantine period. The animals were housed isolated 
at the facilities of the Institute of Primate Research (IPR), 
Karen, Nairobi, Kenya. Ethical clearance for these studies was 
obtained from the Institute for Primate Research IACUC (IPR/
SRP3/2004) and the University of Texas Health Science Center 
at San Antonio IACUC (08039x).
Preparation of the antioxidant Vaccines
cDNA containing the entire open reading frames of SmCT-SOD, 
SmEC-SOD, SmGPX were previously cloned into the eukaryotic 
expression vectors pcDNAI/Amp (pc) (31, 32) and VR1055 
(Vical, San Diego, CA, USA) (33). Each plasmid preparation 
was then purified by double gradient centrifugation in CsCl2, 
dialyzed against PBS to remove the CsCl2, ethanol precipitated, 
and re-suspended in sterile sucrose (25% in PBS). The last boost 
consisted of the respective recombinant proteins incorporated 
into microspheres made of polylactic acid (PLA). Only recom-
binant proteins were incorporated into PLA microspheres, as 
previously described by us (32). Of note, the following terms 
are used interchangeably throughout the study: SmCT-SOD or 
CTSOD; SmEC-SOD or ECSOD; SmGPX or GPX; and Vector 
Only or Control.
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immunizations and challenge
Two vaccination experimental protocols were carried out: 
Experiment 1 (Figure  1A) was for safety and toxicity evalu-
ation after vaccination, while Experiment 2 (Figure  2A) for 
assessment of the efficacy of vaccination upon challenge with 
S. mansoni. In Experiment 1 (Figure 1A), groups of five olive 
baboons received 500 μg of purified DNA via two intramuscular 
(quadriceps) injections with a 26-gage needle in each leg. Each 
group received a second and third 500 μg dose of their respective 
DNA, 4 weeks apart. A fourth dose of 500 μg of recombinant 
proteins encapsulated in PLA microspheres as described (32) 
was given 4 weeks after the third injection. The control animals 
were primed and boosted with empty vector DNA, while the last 
boost consisted of empty PLA microspheres in PBS instead of 
recombinant proteins.
In Experiment 2 (Figure 2A), groups of five 4- to 5-year-old 
olive baboons were primed with 1000 μg of purified DNA, boosted 
once with 1000 μg doses of their respective purified DNA, and once 
with 1000 μg of the respective recombinant protein encapsulated 
in PLA microspheres, with all immunizations 4 weeks apart from 
each other. The control animals were primed and boosted with 
empty vector DNA, while the last boost consisted of empty PLA 
microspheres in PBS instead of recombinant proteins. The baboons 
were then anesthetized using a mixture of xylazine (2% Rompun™) 
and Ketamine hydrochloride (100 mg/ml; Agrar Holland BV, Soest, 
The Netherlands) at a dose of 10 mg/kg body weight. After shaving 
the groin areas of the baboons, 600 cercariae (Kenyan strain) in 
suspension from individual beakers were poured into a groin 
pouch and left to penetrate via the skin for 30 min.
Figure 1 | experiment 1 scheduling and clinical assessment of safety 
and toxicity. In (a), the schematic representation of Experiment 1 protocol 
where olive baboons (n = 5 animals per vaccine group, n = 10 controls) were 
immunized with CTSOD, ECSOD, and GPX DNA-protein based vaccine. For 
safety and toxicity, the animals were monitored daily for appetite, behavior, and 
demeanor observations (data not shown) and bi-weekly for weight and 
temperature. In (B,c), the average results of the bi-weekly monitoring of weight 
(B) and temperature (c) from baboons before and after immunizations with 
antioxidant vaccines during safety and toxicity evaluation. Animals were 
euthanized at week 26 post-immunization.
Blood collection for hematology, cell, and 
serum isolation
All animals were anesthetized with ketamine hydrochloride 
(10 mg/kg body weight) prior to blood collection. Then, a 10 ml 
syringe with a 21-gauge needle was used to draw blood from 
the femoral vein, where it was placed into an EDTA treated 
tube for hematology (Experiment 1) or used for serum collec-
tion (Experiment 2). In addition, 50  ml syringes containing 
20  ml of Alsever’s anti-coagulant solution (Sigma) and fitted 
with a 21-gauge needle were used to draw 20  ml of blood to 
a total volume of 40 ml blood mixture from the opposite limb 
(Experiment 2).
In the Experiment 1, as depicted in Figure 1A, the blood was 
drawn every 2 weeks (with exception of the last time point in which 
blood was taken 3 weeks after last boost). The eight time points 
were: week 0 (pre-immune, PI), week 2 (2 weeks post-priming), 
week 4 (pre-1st boost), week 6 (2  weeks post-1st boost), week 
8 (pre-2nd boost), week 10 (2 weeks post-2nd boost), week 12 
(pre-3rd boost), and week 15 (3 weeks post-3rd Boost). In the 
Experiment 2 (Figure 2A), the blood was drawn at three time-
points: week 0 (pre-immune, PI), week 12 (pre-challenge, PC), 
and week 22 (pre-perfusion, PP).
clinical assessment for safety and Toxicity
The baboons were monitored daily for appetite, behavior, and 
demeanor, and tested at 2-week intervals for temperature, weight 
measurements, complete blood counts, and leukocyte differentials 
at baseline (week 0) and after all immunizations.
Figure 2 | experiment 2 scheduling and clinical assessment after 
challenge infection. In (a), the schematic representation of the Experiment 2 
protocol where olive baboons were immunized with CTSOD, ECSOD, and GPX 
DNA-protein based vaccine (n = 5 animals per each group), and further 
challenged with 600 S. mansoni cercariae. Animals were also assessed for 
safety and toxicity of vaccination (data not shown). In (B,c), commence of 
diarrhea and duration of dysentery in days after challenge infection. Individual 
values (sphere); mean average (dash). The percentage of animals that did not 
suffer diarrhea is represented in (B). In (c), the percentage of reduction 
(represented by the arrow), the range (minimal-maximal, represented between 
brackets), and the statistical p-value were expressed in comparison to the 
mean average of the Control group. Non-parametric (Kruskal–Wallis, Mann–
Whitney) tests were applied. Values were considered statistically significant 
when p < 0.05.
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Perfusion
Approximately 10  weeks post-challenge, the baboons were 
euthanized by intravenous administration of heparinized sodium 
pentobarbital. For each animal, the viscera were exposed after a 
median incision. The gross pathology of the liver, intestines, and 
mesenteric lymph nodes was evaluated. Perfusion of worms from 
the mesenteric vasculature and the liver was achieved after the 
administration of citrated saline through the abdominal aorta, 
as described previously (34), and adult worms were counted. To 
ensure that all worms were recovered, during the perfusion, the 
mesenteric veins were manually searched for schistosome worms. 
The worms were counted, and as an indicator of efficacy, the mean 
percent protection observed in the experimental groups was deter-
mined as the decrease in worm burden of each animal compared 
to the mean recovery of the control groups (35).
Parasitological Parameters
The weekly assessment of eggs per gram of feces (EPG) from vac-
cinated and control baboons commencing 6 weeks after S. mansoni 
cercariae challenge was determined by the thick smear Kato-Katz 
microscope technique (36). For extraction and determination of 
eggs present in organs, 10% tissue samples (by weight) of liver and 
intestines were digested overnight in 5% KOH, as described previ-
ously (37). The eggs were counted and the percentage of reduction 
in egg excretion in stool or tissues calculated in relation to the 
mean average of the control group.
enzyme-linked immunosorbent assay
The titers of IgG antibodies in the baboon sera against recom-
binant antigens derived from S. mansoni were determined by 
ELISA as described with minor modifications (32). Flat-bottom 
96-well polystyrene plates (Maxisorp Nunc, GIBCO, Scotland) 
were coated overnight at 4°C with 50 μl of antigens diluted in 
PBS 0.15 M, pH 7.2 (PBS) at concentration of 5 μg/ml. After 
washing (automatic ELISA Washer – MR 5000, Dynatech) and 
blocking, 50 μl/well of doubling dilution of individual serum or 
pooled sera diluted in PBS-Tween 20, 0.05% PBS-T were added 
to each plate and the plates incubated overnight at 4°C. After 
washing, 50 μl/well of unconjugated goat anti-monkey IgG anti-
bodies (Abd Serotec) were added and the plates were incubated 
1 h at 37°C. After the incubation, the plates were washed, and 
50 μl of alkaline-phosphatase conjugated donkey anti-goat IgG 
antibodies (Abd Serotec) were added to those plates with uncon-
jugated antibody, and the plates were incubated for another 1 h 
at 37°C. Detection of reactivity was performed by using 100 μl/
well of pNPP in diethanolamine (DEA) buffer (pNPP Microwell 
Substrate System, KPL) and the absorbance measured at intervals 
at 405  nm by an automatic ELISA Reader (BIORAD). All the 
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assay conditions were previously set up for optimal concentrations 
through checkerboard and titration curves and all the reagents 
for antibody detection used in this assay were shown to be clear 
of non-specific reactions.
isolation of Peripheral Blood Mononuclear cells 
and Tissue cells for recall Proliferation and 
cytokine culture
The mixture of blood/Alsever’s fluid was layered in two tubes con-
taining 10 ml of density gradient solution (Ficoll-Paque™ Research 
Grade, Pharmacia, Uppsala, Sweden) and centrifuged at 2000 rpm 
for 20 min at room temperature. The peripheral blood mononu-
clear cells (PBMCs) were recovered from the gradient interphase 
of plasma and red blood cells, washed twice in RPMI 1640 medium 
containing 80  μg/ml gentamycin (Life Technologies, UK) by 
centrifuging 2000 rpm for10 min for the first time, and 1500 rpm 
for 10 min for the second time. The pellets were re-suspended in 
10 ml of RPMI 1640 containing 10 μg/ml of Polymixin B, 10% 
FCS (GIBCO, Paisley, UK), 80 μg/ml gentamycin solution, 1% 
glutamine (200 mM), and 25 mM HEPES. For cells derived from 
spleen, mesenteric, and inguinal lymph nodes, the tissues were 
disrupted after having been pressed over a 40 μm cell strainer with 
a help of a syringe plunge. The cells were washed once in RPMI 
1640 medium containing 80 μg/ml gentamycin (Life Technologies, 
UK) by centrifuging 2000 rpm for 10 min before the red blood cells 
were lysed for 10 min with lysing solution. After two more washes, 
the pellet was also re-suspended in 10 ml of RPMI 1640 containing 
10 μg/ml of Polymixin B, 10% FCS (GIBCO, Paisley, UK), 80 μg/
ml gentamycin solution, 1% glutamine (200 mM), and 25 mM 
HEPES. Viable cells were counted in a hemocytometer chamber 
using Trypan Blue dye exclusion (Sigma, St Louis, MO, USA). After 
cell count adjustment, 2 × 105 cells were dispensed with 200 μl of 
RPMI 1640 containing 10% FCS (GIBCO, Paisley, UK), 80 μg/ml 
gentamycin solution, 1% glutamine (200 mM), and 25 mM Hepes 
into triplicate wells of a 96-well microtiter plates containing 20 μl of 
parasite antigen at 5 μg/ml (SWAP, SEA), 10 μg/ml (recombinant 
antigens), or 5 μg/ml of Con A. Plates were cultured at 37°C, 5% 
CO2 for 72 h, when 20 μl of 0.5 μCi of 3H thymidine was added per 
well. After incubation for another 18–20 h, the cells were harvested 
onto fiberglass filter papers before the thymidine incorporation 
was measured using 2 ml of scintillation fluid per filter in a Beta 
counter. Results were expressed as stimulation index (S.I.), the 
ratio of the mean counts per minute (cpm) of triplicate culture 
cells taken up in the presence of the antigen over those obtained 
with medium alone.
For cytokine cultures, 2 × 106 cells were dispensed with 1000 μl 
of RPMI 1640 containing 10% FCS (GIBCO, Paisley, UK), 80 μg/
ml gentamycin solution, 1% glutamine (200 mM), and 25 mM 
HEPES into each well of 48-well tissue culture plates containing 
20 μl of parasite antigen at 25 μg/ml (Schistosome Soluble Worm 
Antigen Preparation, SWAP; Soluble Egg Antigen, SEA), 50 μg/
ml (recombinant antigens), or 25 μg/ml of Con A. After 72 h of 
incubation at 37°C, 5% CO2, about 800 μl of supernatant/well 
were harvested and stored at −70°C until use. Freezing medium 
as 80%FCS/20% dimethyl sulfoxide (DMSO) was used in a drop 
wise manner in order to keep the remaining cells in cryo-freezing 
vials at 1 × 107/ml concentration inside a liquid nitrogen tank.
analysis of soluble cytokines and chemokines 
secretion after antigenic stimulation
Harvested supernatants derived from PBMC cultures after 
stimulation with crude and recombinant antigens were assayed 
simultaneously using a 23-plex Non-Human Primate Cytokine/
Chemokine Immunoassay Milliplex Kit (Millipore, Billerica, MA, 
USA) according to the manufacturer’s instructions, including qual-
ity controls. Briefly, 50 μl of standards or samples were incubated 
with multi-cytokine beads for 2 h in the dark, and following washes 
with a vacuum manifold (Millipore, Billerica, MA, USA) with 
biotinylated reporter for 1.5  h. The plates were then incubated 
with Streptavidin–Phycoerythrin for 30 min before the reaction 
was stopped for data collection in the Luminex 200 instrument 
using Luminex IS 2.3 software (Luminex Corporation, Austin, 
TX, USA) with a minimum of 50 beads per analyte. The resulting 
mean fluorescence intensity (MFI) was normalized and analyzed 
through the BeadView Multiplex Data Analysis Software version 
1.0 (Millipore, Billerica, MA, USA), and expressed in pg/ml. The 
following cytokines and chemokines were assayed: IFN-γ, IL-12, 
IL-4, IL-6, IL-17A, CCL3 (MIP-1α), IL-5, IL-13, CCL2 (MCP-1), 
IL-1β, IL-2, IL-15, CCL4 (MIP-1β), TNF-α, IL-10, TGF-α, IL-1Ra, 
IL-8, GM-CSF, sCD40L, VEGF, G-CSF, IL-18.
statistical analysis
Statistical analyses were performed using GraphPad Prism (Prism 
6 for Mac OS X) software. Parametric tests (ANOVA, student’s 
t-tests) were used after log-transformation with corrections for 
multiple analyses. Otherwise, non-parametric (Kruskal–Wallis, 
Mann–Whitney) tests were applied. Values were considered sta-
tistically significant when p < 0.05, and assigned *p = 0.01–0.05; 
**p = 0.001–0.01; and ***p = <0.001.
results
safety and Toxicity (experiment 1)
As noted in Section “Immunizations and Challenge” and in 
Figure 1A, the Experiment 1 was for safety and toxicity evalu-
ation after vaccination. All animals in the study were examined 
clinically throughout the study. The animals appeared healthy, 
eating normally without any physical signs of toxicity. The weight 
(Figure 1B) and temperature (Figure 1C) of each animal were 
normal throughout the study. In addition, as shown in Tables 1 
and 2, the hematological values of the vaccinated animals remained 
within the normal limits throughout the observation period 
and there were no other clinical adverse signs. In addition, we 
examined the vaccine injection sites following immunization and 
did not observe any significant irritation at the vaccination site 
i.e., baboons did not experience any muscle transient induration, 
granulomas, abscesses, ulcers, cutaneous erythema, inguinal 
lymphadenopathy,or skin swelling at the vaccination sites (data 
not shown). In a similar manner, we examined baboons for adverse 
events due to vaccination in Experiment 2. There were none.
Diarrhea, Duration of Dysentery, and egg 
excretion (experiment 2)
The safety of our vaccine candidates encouraged us to proceed 
with Experiment 2 (outlined in Figure 2A), where groups of five 
TaBle 1 | summary of effects of vaccination in baboons (experiment 1)a.
Week Time point WBc (×103) neu (%) eos (%) Baso (%) lymp (%) Mono (%)
c
T
s
O
D
0 PI 8.84 ± 2.53 61.2 ± 3.7 1 ± 0.71 0 ± 0 34.2 ± 0.96 2.6 ± 1.14
2 Post-I 14.98 ± 5.09 59.2 ± 6.94 1.8 ± 1.30 0 ± 0 35 ± 9.08 3.8 ± 2.17
4 Pre-boost 1 12.66 ± 2.0 58.8 ± 12.58 1.2 ± 1.30 0 ± 0 38.8 ± 11.99 1.2 ± 0.45
6 Post-boost 1 11.48 ± 2.74 45.6 ± 10.78 1.2 ± 2.17 0 ± 0 49.8 ± 10.92 2.6 ± 1.34
8 Pre-boost 2 10.68 ± 2.95 38.2 ± 15.75 2.2 ± 2.17 0 ± 0 59 ± 16.73 0.6 ± 0.89
10 Post-boost 2 16.86 ± 4.77 41.6 ± 9.18 3.2 ± 1.64 0 ± 0 55 ± 8.34 0.2 ± 0.45
12 Pre-boost 3 12.52 ± 4.04 50.4 ± 17.56 2.4 ± 1.67 0 ± 0 46.4 ± 16.52 0.6 ± 0.89
15 Post-boost 3 9.08 ± 2.48 47 ± 14.02 1 ± 0 0.4 ± 0.55 51.2 ± 13.99 0.4 ± 0.89
g
P
X
0 PI 11.62 ± 3.71 57.8 ± 14.97 1 ± 1.0 0 ± 0 37 ± 15.44 2.8 ± 0.84
2 Post-I 10.32 ± 2.66 46.5 ± 7.05 0.7 ± 0.5 0.25 ± 0.5 49.5 ± 7.72 2.75 ± 0.96
4 Pre-boost 1 10.46 ± 2.37 44.4 ± 14.71 0.2 ± 0.45 0.2 ± 0.45 53 ± 14.18 2.2 ± 0.84
6 Post-boost 1 12.92 ± 3.27 36.2 ± 4.44 0.6 ± 0.55 0 ± 0 59.8 ± 4.09 3.4 ± 1.52
8 Pre-boost 2 12.56 ± 2.17 51.2 ± 10.92 0.8 ± 1.30 0 ± 0 44.6 ± 9.94 2.2 ± 0.84
10 Post-boost 2 18.9 ± 5.03 30.8 ± 13.54 0.6 ± 0.89 0 ± 0 67.6 ± 11.93 1 ± 1.73
12 Pre-boost 3 13.52 ± 2.53 40.4 ± 20.44 1 ± 0.71 0 ± 0 57.6 ± 20.01 1 ± 2.24
15 Post-boost 3 15.54 ± 4.58 66.2 ± 5.17 1 ± 2.24 0 ± 0 32 ± 4.53 0.6 ± 0.55
c
o
nt
ro
l
Normal range 6–25.3 21–81 0–6 0–1 17–83 0–5
aCTSOD n = 5, GPX n = 5, Control n = 10. 
Values are expressed as mean average ± SD. 
PI, pre-immune; Post-I, post-immune; WBC, total leukocyte count; Neu, neutrophils; Eos, eosinophils; Bas, basophils; Lymp, lymphocytes; Mono, monocytes.
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baboons each were vaccinated with CTSOD and GPX, as well as 
ECSOD, and challenged with 600 S. mansoni cercariae. Weekly 
clinical analysis demonstrated that all three vaccinated groups had 
higher percentage of animals without diarrhea (CTSOD = 60%, 
ECSOD = 60%, and GPX = 40%) upon the onset of egg deposition 
when compared to only 20% in the Control group (Figure 2B). 
In addition, animals vaccinated with antioxidants showed fewer 
mean days of dysentery compared to controls (Figure 2C), where 
CTSOD group presented with a mean reduction of 75% (ranging 
from 100 to 17%), ECSOD with 63% (ranging from 100 to 0%), 
and GPX with 25% (ranging from 100 to 0%).
The weekly assessment of the EPG commencing 6 weeks after 
challenge showed that vaccinated groups had an overall reduction 
of eggs when compared to the Control group (Figures  3A–F). 
This reduction was statistically significant within ECSOD at 
week 8 (Figure 3C) when compared to the unvaccinated Control 
group. When the total EPG over a 5-week period was analyzed, 
all vaccinated groups showed reduction of excreted eggs, specially 
TaBle 2 | summary of effects of vaccination in baboons (experiment 1)a.
Week Time point rBc (×106) hb (g/dl) PVc (%) McV (fl) Mch (pg) Mchc(g/dl)
c
T
s
O
D
0 PI 4.302 ± 0.3 12.94 ± 0.93 38.8 ± 2.77 90.72 ± 11.5 30.26 ± 3.83 33.3 ± 0
2 Post-I 4.06 ± 0.17 12.58 ± 0.36 33.5 ± 1.52 82.4 ± 1.12 30.98 ± 1.2 37.52 ± 1.48
4 Pre-boost 1 4.626 ± 0.29 13.64 ± 0.15 37.86 ± 2.48 82.04 ± 1.66 29.54 ± 1.91 36 ± 2.29
6 Post-boost 1 4.166 ± 0.23 13 ± 0.19 33.46 ± 2.69 80.3 ± 3.46 31.24 ± 1.81 39.02 ± 3.55
8 Pre-boost 2 4.398 ± 0.35 13.56 ± 0.48 35.42 ± 4.46 80.34 ± 4.57 30.94 ± 2.58 38.7 ± 4.68
10 Post-boost 2 4.634 ± 0.19 14.56 ± 0.21 39.04 ± 2.47 84.2 ± 2.37 31.4 ± 1.63 38.6 ± 2.58
12 Pre-boost 3 4.248 ± 0.26 11.94 ± 1.15 35.42 ± 2.75 83.32 ± 3.24 27.92 ± 2.3 33.54 ± 3.04
15 Post-boost 3 5.022 ± 0.19 12.34 ± 1.1 34.42 ± 1.20 68.5 ± 2.96 24.56 ± 2.12 35.88 ± 3.82
g
P
X
0 PI 4.264 ± 0.51 13.14 ± 0.76 40.34 ± 1.93 95.24 ± 9.91 31.28 ± 3.57 33.3 ± 0
2 Post-I 4.59 ± 0.39 12.77 ± 0.55 38.25 ± 3.29 83.35 ± 0.17 27.9 ± 2.03 33.55 ± 2.6
4 Pre-boost 1 4.79 ± 0.24 14.6 ± 0.86 39.92 ± 2.23 83.08 ± 2.98 31.08 ± 1.87 36.6 ± 2.95
6 Post-boost 1 4.532 ± 0.43 13.78 ± 0.74 38.36 ± 6.42 88 ± 14.44 30.48 ± 1.46 35.58 ± 6.35
8 Pre-boost 2 4.596 ± 0.26 14.64 ± 0.88 36.48 ± 2.06 79.36 ± 0.96 31.8 ± 0.23 40.08 ± 0.57
10 Post-boost 2 4.348 ± 0.23 14.86 ± 0.96 36.42 ± 2.25 83.7 ± 1.46 34.14 ± 1.32 40.78 ± 1.99
12 Pre-boost 3 4.554 ± 0.26 11.92 ± 0.34 39.82 ± 4.49 87.14 ± 4.91 26.18 ± 1.92 30.12 ± 3.99
15 Post-boost 3 5.286 ± 0.52 13.58 ± 0.89 35.9 ± 3.23 68.1 ± 1.81 25.76 ± 2.17 37.96 ± 3.51
c
o
nt
ro
l
Normal range 3.64–5.36 11.3–14.5 27.7–49.3 65.4–102 23.5–35.2 28.9–44.4
aCTSOD n = 5; GPX n = 5; Control n = 10. 
Values are expressed as mean average ± SD. 
PI, pre-immune; Post-I, post-immune; RBC, erythrocyte count; Hb, hemoglobin concentration; PVC, packed cell volume; MCV, mean corpuscular volume; MCH, mean corpuscular 
hemoglobin; MCHC, mean corpuscular hemoglobin concentration.
Figure 3 | Dynamics of weekly egg excretion per gram of feces 
(ePg) from experiment 2. Assessment of eggs per gram of feces (EPG) 
from vaccinated and control baboons (n = 5 animals per group) 
commencing 6 weeks after S. mansoni cercariae challenge: weekly overview 
(a); week 7 (B); week 8 (c); week 9 (D); week 10 (e); and the total EPG 
excreted over 5 weeks period (F). The statistical p-value was expressed in 
comparison to the mean average of the Control group. Results were 
log-transformed and corrected for multiple analyses when applying ANOVA 
and student’s t-tests. Values were considered statistically significant when 
p < 0.05.
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ECSOD vaccinated animals who showed statistically significant 
reduction when compared to the Control (Figure 3F).
Tissue eggs from liver, small gut, and large 
gut (experiment 2)
The distribution of eggs recovered in harvested organs after KOH 
digestion from vaccinated and control baboons 10  weeks after 
challenge at perfusion time point is shown in Figure 4. There was 
an overall reduction of eggs in all vaccinated groups in the liver, 
small gut, and large gut when compared to the Control group. 
The egg reduction in the liver (Figure 4A) ranged from 56 to 0% 
for CTSOD, 84 to 3% for ECSOD, and 56 to 0% for GPX, while in 
the small gut (Figure 4B), the reduction in CTSOD group ranged 
from 64 to 0%, ECSOD ranged from 88 to 0%, and GPX ranged 
from 100 to 0%. When the large gut was evaluated (Figure 4C), 
egg reduction ranged from 70 to 0% for CTSOD, 93 to 0% for 
ECSOD, and 89 to 0% for GPX, when compared to the mean 
average of Control group.
Worm Burden/Percentage of Protection 
(experiment 2)
When the distribution of worms (Figure 5A), males (Figure 5B), 
and females (Figure 5C) recovered from outbred vaccinated and 
control baboons 10 weeks after challenge with S. mansoni cercariae 
was evaluated at the perfusion time point, ECSOD vaccinated 
group showed a reduction of total worms that ranged from 89 
to 0% (mean protection 19.5%), while GPX group showed a 
reduction that ranged from 47 to 0% (mean protection 17.1%) 
Figure 4 | Distribution of eggs recovered in tissues from 
experiment 2. Liver (a), small gut (B), and large gut (c) eggs after KOH 
digestion from vaccinated and control baboons (n = 5 animals per group) 
0 weeks after challenge with S. mansoni cercariae (perfusion time point). 
Individual values (sphere); mean average (dash). The percentage of 
reduction (represented by the arrow), the range (minimal–maximal, 
represented between brackets), and the statistical p-value were expressed 
in comparison to the mean average of the Control group. Non-parametric 
(Kruskal–Wallis, Mann–Whitney) tests were applied. Values were considered 
statistically significant when p < 0.05.
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of worms when compared to the Control group (Figure 5A). The 
same pattern was observed when worms were stratified into males 
(Figure 5B) and females (Figure 5C). The CTSOD group failed 
to show a mean reduction in worms, although reduction in two 
vaccinated baboons (out of five) is visible.
antibody response (experiment 2)
Titration of baboon sera against recombinant antigens showed 
that levels of specific IgG antibodies were stimulated after immu-
nizations (PC) with CTSOD (Figure  6A) as well as with GPX 
(Figure  6D), and to a lesser degree with ECSOD (Figure  6B), 
when compared to control sera (Figures 6C,E). Antibody levels 
continued to be elevated 10 weeks after challenge infection (PP) 
for CTSOD and GPX groups.
Figure 5 | Distribution of worms recovered (worm burden) from 
experiment 2. Total worm burden (a), male (B) and female (c) worm 
count. Worms from vaccinated and control baboons (n = 5 animals per 
group) 10 weeks after challenge with S. mansoni cercariae (perfusion 
time point). Individual values (sphere); mean average (dash). The 
percentage of reduction (represented by the arrow), the range (minimal–
maximal, represented between brackets), and the statistical p-value were 
expressed in comparison to the mean average of the Control group. Non-
parametric (Kruskal–Wallis, Mann–Whitney) tests were applied. Values 
were considered statistically significant when p < 0.05.
Figure 6 | antibody response from experiment 2.Titration of baboon IgG antibodies against recombinant SOD (a–c) and GPX (D–e) from CTSOD (a), ECSOD 
(B), GPX (D), and Control (c,e) groups (n = 5 animals per group) before (PI), after immunizations (pre-challenge, PC), and before perfusion (pre-perfusion, PP).
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of worms when compared to the Control group (Figure 5A). The 
same pattern was observed when worms were stratified into males 
(Figure 5B) and females (Figure 5C). The CTSOD group failed 
to show a mean reduction in worms, although reduction in two 
vaccinated baboons (out of five) is visible.
antibody response (experiment 2)
Titration of baboon sera against recombinant antigens showed 
that levels of specific IgG antibodies were stimulated after immu-
nizations (PC) with CTSOD (Figure  6A) as well as with GPX 
(Figure  6D), and to a lesser degree with ECSOD (Figure  6B), 
when compared to control sera (Figures 6C,E). Antibody levels 
continued to be elevated 10 weeks after challenge infection (PP) 
for CTSOD and GPX groups.
Figure 5 | Distribution of worms recovered (worm burden) from 
experiment 2. Total worm burden (a), male (B) and female (c) worm 
count. Worms from vaccinated and control baboons (n = 5 animals per 
group) 10 weeks after challenge with S. mansoni cercariae (perfusion 
time point). Individual values (sphere); mean average (dash). The 
percentage of reduction (represented by the arrow), the range (minimal–
maximal, represented between brackets), and the statistical p-value were 
expressed in comparison to the mean average of the Control group. Non-
parametric (Kruskal–Wallis, Mann–Whitney) tests were applied. Values 
were considered statistically significant when p < 0.05.
cMi Proliferation/recall responses (experiment 2)
Recall proliferation assays from PBMCs (Figures  7A–C) were 
performed against crude and recombinant antigens before (pre-
immune, PI), after immunizations (pre-challenge, PC), and after 
challenge with S. mansoni at the perfusion time point (PP). The 
recall proliferation assays for mesenteric (MLN) and inguinal (ILN) 
lymph nodes (Figures 7D–E) were performed only at the time of 
the perfusion (PP). All results were expressed as Stimulation Index 
(S.I.): the ratio of the mean cpm of triplicate culture cells taken up 
in the presence of the antigen over those obtained with medium 
alone. PBMC (Figures  7A,B) and MLN cells (Figures  7D,E) 
from both CTSOD and ECSOD groups proliferated in response 
to recombinant CTSOD antigens when compared with Control. 
Similarly, PBMC (Figure  7C), mesenteric, and inguinal node 
Figure 7 | recall proliferation assays from experiment 2. PBMC (a–c) 
and mesenteric (MLN) and inguinal (ILN) lymph nodes (D–F) against crude and 
recombinant antigens from CTSOD (a,D), ECSOD (B,e), GPX (c,F), and 
Control groups (n = 5 animals per group) before (PI), after immunizations 
(pre-challenge, PC), and after challenge with S. mansoni at the perfusion time 
point (PP). Results were expressed as Stimulation Index (S.I.), the ratio of the 
mean counts per minute (cpm) of triplicate culture cells taken up in the 
presence of the antigen over those obtained with medium alone. Non-
parametric (Kruskal–Wallis, Mann–Whitney) tests were applied. Values were 
considered statistically significant when p < 0.05.
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cells (Figure  7F) from GPX vaccinated animals proliferated in 
response to recombinant antigens in comparison with Control 
group. PBMC and MLN from all groups responded to SEA and 
SWAP after challenge with S. mansoni cercariae (Figures 7D–F).
secretion of cytokines and chemokines upon 
stimulation (experiment 2)
A panel of 23 multiplexed IFN-γ, IL-12, IL-4, IL-6, IL-17A, CCL3 
(MIP-1α), IL-5, IL-13, CCL2 (MCP-1), IL-1β, IL-2, IL-15, CCL4 
(MIP-1β), TNF-α, IL-10, TGF-α, IL-1Ra, IL-8, GM-CSF, sCD40L, 
VEGF, G-CSF, IL-18 cytokines and chemokines (Figures 8–11; 
Figures S1 and S2 in Supplementary Material) was used to investi-
gate secretion from individual supernatants derived from PBMCs 
from CTSOD (A, D, G), ECSOD (B, E, H), and GPX (C, F, I) groups 
after 72 h stimulation with crude and recombinant antigens at all 
time points: before vaccination (PI), before challenge (PC), and 
at perfusion (PP). Values were expressed as median of cytokine 
secretion from five individual supernatants.
In general, vaccination with ECSOD and CTSOD induced 
variable levels of cytokines before challenge (PC) upon stimulation 
with recombinant antigens when compared to the baseline levels 
(PI), although these levels were somewhat discrete. However, vac-
cination with GPX induced higher levels of IL-5 (Figure 8F) and 
IL-17A (Figure 9I) cytokines, and reduction of IL-8 (Figure 10F) 
and chemokines such as CCL2, CCL3, and CCL4 (Figures 11C,F,I) 
when compared to Control. CTSOD vaccination induced increase 
in the IL-17A levels (Figure  9G), while a reduction of IL-1β, 
IL-18 (Figures  10A,B,G,H) cytokines, and CCL3 and CCL4 
(Figures 11C,I) chemokines in CTSOD and ECSOD groups was 
also observed, when compared to Control.
After challenge, several cytokine and chemokine levels increased 
in the vaccinated groups after the natural boost provided from 
the infection with S. mansoni (Figures 8–11). For instance, high 
levels of IL-4, IL-5, IL-13 (Figures 8A–I), IFN-γ (Figures 9A–C) 
cytokines were stimulated after challenge (PP) against SWAP and 
SEA in the CTSOD, ECSOD, and GPX groups when compared 
Figure 8 | secretion of cytokines in supernatants from experiment 2. 
PBMCs from CTSOD (a,D,g), ECSOD (B,e,h), and GPX (c,F,i) groups 
(n = 5 animals per group) were stimulated 72 h with crude and recombinant 
antigens and secreted IL-4, IL-5, and IL-13 levels determined, before 
vaccination (PI), before challenge (PC), and at perfusion (PP). Values were 
expressed as median of cytokine secretion in five individual supernatants in 
relation to the Control baboons. Non-parametric (Kruskal–Wallis, Mann–
Whitney) tests were applied. Values were considered statistically significant 
when p < 0.05, and assigned *p = 0.01–0.05; **p = 0.001–0.01; and 
***p = <0.001.
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to (PC) levels, and this response was higher in the vaccinated 
groups when compared to the control group. The levels of IL-15 
(Figures 9D–F) were also increased, especially in the GPX group, 
before perfusion (PP) when compared to control.
Discussion
As mentioned previously, our laboratory has demonstrated that 
vaccination of inbred mice with naked DNA constructs containing 
Cu/Zn cytosolic superoxide dismutase (CT-SOD), signal-peptide 
containing SOD (EC-SOD), or glutathione peroxidase (GPX) 
derived from S. mansoni showed significant levels of protection 
compared to a control group (29). Screening of candidate antigens 
in mice is an important first step in vaccine development but it 
is unclear whether protective efficacy can be translated directly 
to humans (38). Therefore, our murine results encouraged us to 
investigate if immunization of non-human primates with these 
antioxidants would stimulate an immune response that could be 
correlated with protection as a prelude study for human trials. 
Baboons are an excellent model for schistosomiasis, as they are 
similar to humans in ontogeny, immune response (including 
human-like IgG subclasses), reproductive physiology, etc., and 
develop a human-like acute disease after natural or experimental 
exposure to S. mansoni (38–40). In addition, since issues of vaccine 
safety are also difficult to address in mice, another advantage of 
testing schistosome vaccines in baboons is the opportunity to 
address many of the deficiencies of mouse studies (38–41). We 
have also previously used baboons to successfully investigate the 
immune mechanisms associated with other schistosome vaccine 
candidates (42). Overall, our data indicate that no adverse reactions 
or abnormal animal demeanor occurred to the immunization of 
baboons with antioxidants, as our behavioral, clinical, and hema-
tological evaluations of the vaccinated animals remained within 
the normal limits throughout the observation period for both 
experiments. Thus the vaccines are safe and well tolerated.
The next step was to check the antigenicity of the antioxidants 
after vaccination with baboons, as the dose and nature of the antigen 
as well as the route or kind of adjuvant used can ultimately dictate 
the outcome of an immunization, among other factors. Plasmid/
naked DNA vaccines are less toxic, but also less immunogenic, 
therefore potent and safe adjuvants that can be used as vaccine 
delivery systems and as immunostimulatory adjuvants are neces-
sary (43). Biodegradable and biocompatible polyester polymers 
such as PLA to encapsulate antigens (44–46) have been successfully 
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used in applications ranging from cancer therapy to infectious dis-
eases (47–50). The enhanced adjuvant effect of such microparticles 
appears to be a consequence of efficient and controlled delivery 
of the adsorbed proteins into dendritic cells and macrophages at 
the injection site and local lymph nodes (51, 52). In the murine 
model, we showed that along with DNA immunization, one single 
dose of SmCT-SOD proteins encapsulated in PLA microspheres, 
for instance, was able to induce high titers of specific antibodies 
in immunized mice (32). Therefore, in our baboon studies, we 
evaluated if the immunization protocol of priming with naked 
DNA and boosting with the respective antioxidant proteins 
encapsulated in PLA microspheres could meet or even enhance 
the immunogenicity and protection levels achieved by prime-boost 
immunization with DNA only. All three antioxidant vaccines were 
immunogenic to different degrees, stimulating both humoral 
and cellular responses (including cytokines and chemokines). 
As observed previously by us and by other studies, the specific 
antibody and cellular responses primed by DNA vaccination 
were boosted by infection. This natural boosting is believed to be 
beneficial in endemic areas where individuals are continuously 
exposed to the parasite (31, 53, 54).
Numerous studies on individuals in endemic areas for 
Schistosoma showed that parasite-specific humoral and cellular 
responses vary in their correlation with the development of resist-
ance and/or susceptibility/morbidity to infection/re-infection 
(55–57). And an increasing body of evidence indicates that a 
balance between innate cells and CD4+ T helper (Th) cells Th1, 
Th2, Th17, and Treg responses (which cross-regulate one another 
during infection) rather than a polarizing effect (e.g., Th1 vs Th2) 
is likely beneficial in the development of protection against S. 
mansoni infections, both in humans and experimental models 
(58–61). Moreover, it is becoming evident that the interaction 
between these responses rather than just the levels of individual 
cytokines alone may influence outcomes such as resistance to 
reinfection (62, 63).
In our study, a mixed cytokine/chemokine response was 
observed, where the S. mansoni infection stimulated a Th2 
response in all groups as well as an inflammatory profile that dif-
fered from controls. Although it was clear that vaccination with 
ECSOD, CTSOD, and GPX stimulated different responses when 
compared to the control group. The specific role of antibodies 
or cellular responses and the development of protection against 
Figure 9 | secretion of cytokines in supernatants from experiment 2. 
PBMCs from CTSOD (a,D,g), ECSOD (B,e,h), and GPX (c,F,i) groups 
(n = 5 animals per group) were stimulated 72 h with crude and recombinant 
antigens and secreted IFN-γ, IL-15, and IL-17A levels determined, before 
vaccination (PI), before challenge (PC), and at perfusion (PP). Values were 
expressed as median of cytokine secretion in five individual supernatants in 
relation to the Control baboons. Non-parametric (Kruskal–Wallis, Mann–
Whitney) tests were applied. Values were considered statistically significant 
when p < 0.05, and assigned *p = 0.01–0.05; **p = 0.001–0.01; and 
***p = <0.001.
June 2015 | Volume 6 | Article 27313
Carvalho-Queiroz et al. Antioxidant vaccination reduces Schistosoma pathogenicity
Frontiers in Immunology | www.frontiersin.org
challenge with S. mansoni is still unknown, and currently under 
investigation. As shown by Mola et  al. (64), the levels of most 
cytokines produced by PBMC or antibodies vary depending on 
whether the baboons experienced a primary infection compared 
to re-infection with S. mansoni. Although the young baboons used 
in this study were caught in the wild from non-endemic areas 
and were quarantined and checked for the presence of current 
schistosomiasis infection (and other infections), we cannot rule 
out the possibility that some of these animals were infected prior 
to the beginning of our study, therefore influencing the cytokine 
responses. However, this in fact would most likely resemble the 
situation in endemic areas, where people in endemic areas would 
be exposed to one or multiple infections or none at all before vac-
cination with antioxidants, and in many instances, such exposure 
to worm antigens in humans would have occurred very early in life 
during childhood or even in utero (65, 66), which makes outbred 
baboons ideally suited for such studies.
In schistosomiasis, pathogenesis is mainly caused by the immu-
nological reaction of the host to the eggs (and their secretions) 
released by adult worm pairs that inhabit the portal circulation. 
Consequently, the severity of the disease is directly related to the 
worm burden and the inflammatory response to deposited eggs 
(67). For instance, as recently reviewed (68), the chemokines 
CCL2, CCL3, and CCL4 correlate with the severity of S. mansoni, 
where CCL3 is related to the recruitment of eosinophils and induc-
tion of granulomatous pathology (69), while CCL2 is associated 
with glomerulopathy (70). A more “traditional” vaccine concept 
would target a reduction of the worm number or even prevent 
infection. However, since the released eggs are responsible for 
both transmission and pathology, a vaccine targeted at parasite 
fecundity and egg viability has become relevant (71, 72). The 
vaccination of baboons with antioxidants in the present study 
stimulated a partial reduction in the worm burden, which was in 
sharp contrast with our previous studies in mice (29). However, 
vaccination with antioxidants, especially ECSOD, promoted a 
strong anti-fecundity and anti-pathology effect, by means of an 
overall reduction of eggs in all vaccinated groups in the feces, liver, 
small gut, and large gut, as well as reduction of diarrhea (dysentery) 
when compared to the Control group. One of the hallmarks of 
pathology, diarrhea normally occurs during moderate and heavy 
S. mansoni infections due to eggs released by the worms, which 
in turn induce an immunological response leading to pathology 
Figure 10 | secretion of cytokines in supernatants from experiment 
2. PBMCs from CTSOD (a,D,g), ECSOD (B,e,h), and GPX (c,F,i) groups 
(n = 5 animals per group) were stimulated 72 h with crude and recombinant 
antigens and secreted IL-1β, IL-8, and IL-18 levels determined, before 
vaccination (PI), before challenge (PC), and at perfusion (PP). Values were 
expressed as median of cytokine secretion in five individual supernatants in 
relation to the Control baboons. Non-parametric (Kruskal–Wallis, Mann–
Whitney) tests were applied. Values were considered statistically significant 
when p < 0.05, and assigned *p = 0.01–0.05; **p = 0.001–0.01; and 
***p = <0.001.
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in the intestine wall (67). In our study, diarrhea was reduced in 
all vaccinated groups, in particular in the CTSOD and ECSOD 
groups. Other studies had reported both immune responses and 
anti-fecundity effects against female worms with glutathione-S-
transferase, SmGST (73, 74), as well as the large subunit of calpain, 
Sm-p80 (75). Interestingly, the significant reduction in fecundity 
in this study was in spite of the small reduction in worm burden. 
The mechanism of the anti-fecundity effect by antioxidants or any 
other vaccine candidate, which seems to be independent of worm 
burden, remains to be determined.
Taken together, our results challenge the common concept for 
markers and correlates of protection, since in despite of the lower 
than 40% worm reduction, as set by WHO, the high anti-fecundity/
anti-pathology effect observed by means of reduction of eggs 
and overall pathology indicates that these antioxidants vaccines 
could prevent intestinal pathology and therefore warrants further 
investigation. In addition, the use of outbred juvenile baboons 
more accurately reflects the human situation as regards response to 
vaccination and subsequent challenge infection. Experiments with 
different vaccine regimens (including multivalent immunizations), 
delivery modes, and adjuvants in the baboon model are planned 
for the near future.
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abstract
Figure 11 | secretion of chemokines in supernatants from experiment 
2. PBMCs from CTSOD (a,D,g), ECSOD (B,e,h), and GPX (c,F,i) groups 
(n = 5 animals per group) were stimulated 72 h with crude and recombinant 
antigens and secreted CCL2 (MCP-1), CCL3 (MIP-1α), and CCL4 (MIP-1β) 
levels determined, before vaccination (PI), before challenge (PC), and at 
perfusion (PP). Values were expressed as median of cytokine secretion in five 
individual supernatants in relation to the Control baboons. Non-parametric 
(Kruskal–Wallis, Mann–Whitney) tests were applied. Values were considered 
statistically significant when p < 0.05, and assigned *p = 0.01–0.05; 
**p = 0.001–0.01; and ***p = <0.001.
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